Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Irregularity measures tend to describe the complexity of networks. Chemical graph theory is a branch of mathematical chemistry that has a significant impact on the development of the chemical sciences ...
This important study introduces a biologically constrained model of telencephalic area of adult zebrafish to highlight the significance of precisely balanced memory networks in olfactory processing.
As a consequence, the boundary indicator of a boundary part in 1d (i.e. either the left or right vertex) were determined by convention, rather than by setting it explicitly: the left boundary of a 1d ...
School of Materials Sciences, Indian Association for the Cultivation of Science, Kolkata 700032, India ...